Search

Mark S Todtenkopf

from Sneads Ferry, NC
Age ~54
Get Report
Also known as:
Mark R Todtenkopf, Mark S Todtenkoff, Mark Todtenkopf Ret, Mark F
Connected to:
David R Todtenhagen, 65Jay N Todtman, 72Andrew C Todtz, 57Samuel L Todwong, 70Loretta B Todzia, 47Jean Todzy, 53Adama L Toe, 50Jeffrey L Toe, 43Randull Toe, 56Raluca A Toea, 39

Mark Todtenkopf Phones & Addresses

  • Sneads Ferry, NC
  • 103 Highwood Dr, Franklin, MA 02038 (508) 541-4675
  • 4 Stephen Way, Franklin, MA 02038 (508) 520-1120
  • 99 Hayward St, Franklin, MA 02038 (508) 520-1120
  • Milford, MA
  • Waltham, MA
  • Cambridge, MA
  • Belmont, MA
  • Lexington, MA
  • Medford, MA
  • Marlborough, MA

Resumes

Resumes

Mark Todtenkopf Photo 1

Associate Director, Scientific Communications

View page
Location:
265 Olinger Cir, Wilmington, OH 45177
Industry:
Research
Work:
Alkermes since Feb 2006
Senior Scientist
McLean Hospital Jan 2004 - Feb 2006
Instructor in Psychiatry, Harvard Medical School
Harvard Medical School / McLean Hospital Dec 2001 - Dec 2003
Post-Doctoral Fellow
Education:
Northeastern University 1997 - 2001
Ph.D., Experimental Psychology Northeastern University 1997 - 1999
M.A., Experimental Psychology University of Massachusetts, Amherst 1989 - 1993
B.S., Psychology/Neuroscience
Skills:
Neuroscience
Drug Discovery
In Vivo
Life Sciences
Drug Development
Pharmaceutical Industry
Pharmacology
Animal Models
Assay Development
Scientific Writing
Immunohistochemistry
Science
Western Blotting
Neuropharmacology
Clinical Development
Lifesciences
Microscopy
Medical Writing
Translational Research
Elisa
Development and Production of Publications
Scientific Communications
Medical Affairs
Languages:
English
Spanish
Mark Todtenkopf Photo 2

Senior Scientist, Alkermes, Inc.

View page
Position:
Senior Scientist at Alkermes
Location:
Greater Boston Area
Industry:
Research
Work:
Alkermes since Feb 2006
Senior Scientist
McLean Hospital Jan 2004 - Feb 2006
Instructor in Psychiatry, Harvard Medical School
Harvard Medical School / McLean Hospital Dec 2001 - Dec 2003
Post-Doctoral Fellow
Education:
Northeastern University 1997 - 2001
Ph.D., Experimental Psychology Northeastern University 1997 - 1999
M.A., Experimental Psychology University of Massachusetts, Amherst 1989 - 1993
B.S., Psychology/Neuroscience
Skills:
Neuroscience
Pharmacology
Drug Discovery
ELISA
Western Blotting
Animal Models
Immunohistochemistry
In Vivo
Lifesciences
Microscopy
Drug Development
Neuropharmacology
Pharmaceutical Industry
Medical Writing
Scientific Writing

Business Records

Name / Title
Company / Classification
Phones & Addresses
Mark Todtenkopf
Principal
Todtenkopf
Nonclassifiable Establishments
99 Hayward St, Franklin, MA 02038

Publications

Us Patents

Selective Opioid Compounds

View page
US Patent:
20090209569, Aug 20, 2009
Filed:
Feb 13, 2009
Appl. No.:
12/371334
Inventors:
Derrick Arnelle - Arlington MA, US
Daniel Deaver - Franklin MA, US
Mark Todtenkopf - Franklin MA, US
Assignee:
Alkermes, Inc. - Cambridge MA
International Classification:
A61K 31/485
C07D 489/08
A61P 25/00
US Classification:
514282, 546 46
Abstract:
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to morphinan compounds useful as μ, δ, and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

Methods For Treating Antipsychotic-Induced Weight Gain

View page
US Patent:
20120077800, Mar 29, 2012
Filed:
Aug 23, 2011
Appl. No.:
13/215718
Inventors:
Daniel Deaver - Franklin MA, US
Mark Todtenkopf - Franklin MA, US
Assignee:
Alkermes, Inc. - Waltham MA
International Classification:
A61K 31/485
A61K 31/519
A61P 3/04
A61K 31/496
A61P 25/18
A61K 31/551
A61K 31/554
US Classification:
51421113, 514289, 514220, 5142641, 51425307, 51425404
Abstract:
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Peripherially Acting Μ Opioid Antagonists

View page
US Patent:
20120245193, Sep 27, 2012
Filed:
Feb 14, 2012
Appl. No.:
13/396152
Inventors:
Bernard Silverman - Needham MA, US
Mark Todtenkopf - Franklin MA, US
Daniel Deaver - Franklin MA, US
Lauren DiPetrillo - Somerville MA, US
International Classification:
A61K 31/485
C07D 221/28
C07D 489/08
A61P 1/00
US Classification:
514282, 514289, 546 74, 546 45
Abstract:
The present invention relates to a novel functional peripherally-acting μ opioid receptor antagonist of Formula I:The novel compounds of the present invention have reduced oral bioavailability without compromising opiate-induced analgesia in the CNS. The compounds of the present invention are further efficacious at low doses and are useful in treating gastrointestinal conditions associated with opioid analgesic therapy.

Selective Opioid Compounds

View page
US Patent:
20140005215, Jan 2, 2014
Filed:
Dec 4, 2012
Appl. No.:
13/693662
Inventors:
Daniel Deaver - Franklin MA, US
Mark Todtenkopf - Franklin MA, US
Assignee:
Alkermes, Inc. - Waltham MA
International Classification:
C07D 489/08
A61K 45/06
C07D 471/08
A61K 31/485
US Classification:
514282, 514289
Abstract:
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:which relates to mophinan compounds useful as μ, δ and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

Methods For Treating Antipsychotic-Induced Weight Gain

View page
US Patent:
20220280502, Sep 8, 2022
Filed:
Oct 20, 2021
Appl. No.:
17/505896
Inventors:
- Dublin, IE
Mark Todtenkopf - Franklin MA, US
International Classification:
A61K 31/485
A61K 31/439
A61K 31/496
A61K 31/519
A61K 31/5513
A61K 31/554
C07D 221/28
C07D 405/06
A61K 9/20
A61K 31/551
Abstract:
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Methods For Treating Antipsychotic-Induced Weight Gain

View page
US Patent:
20210046065, Feb 18, 2021
Filed:
Oct 15, 2020
Appl. No.:
17/071236
Inventors:
- Dublin, IE
Mark Todtenkopf - Franklin MA, US
International Classification:
A61K 31/485
C07D 221/28
A61K 9/20
A61K 31/439
A61K 31/496
A61K 31/5513
A61K 31/551
A61K 31/554
C07D 405/06
A61K 31/519
Abstract:
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Methods For Treating Antipsychotic-Induced Weight Gain

View page
US Patent:
20210038594, Feb 11, 2021
Filed:
Oct 15, 2020
Appl. No.:
17/071166
Inventors:
- Dublin, IE
Mark Todtenkopf - Franklin MA, US
International Classification:
A61K 31/485
C07D 221/28
A61K 9/20
A61K 31/439
A61K 31/496
A61K 31/5513
A61K 31/551
A61K 31/554
C07D 405/06
A61K 31/519
Abstract:
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.

Methods For Treating Antipsychotic-Induced Weight Gain

View page
US Patent:
20210015812, Jan 21, 2021
Filed:
Jun 12, 2020
Appl. No.:
16/899708
Inventors:
- Dublin, IE
Mark Todtenkopf - Franklin MA, US
International Classification:
A61K 31/485
A61K 31/439
A61K 31/496
A61K 31/519
A61K 31/5513
A61K 31/554
C07D 221/28
C07D 405/06
A61K 9/20
A61K 31/551
Abstract:
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Control profile
Mark S Todtenkopf from Sneads Ferry, NC, age ~54 Get Report